American Society of Clinical Oncology/College of\ud American Pathologists guideline recommendations for\ud immunohistochemical testing of estrogen and\ud progesterone receptors in breast cancer

Article English OPEN
Hammond, M. E. H. ; Hayes, D. F. ; Dowsett, M. ; Allred, D. C. ; Hagerty, K. L. ; Badve, S. ; Fitzgibbons, P. L. ; Francis, G. ; Goldstein, N. S. ; Hayes, M. ; Hicks, D. G. ; Lester, S. ; Love, R. ; Mangu, P. B. ; McShane, L. ; Miller, K. ; Osbourne, C. K. ; Paik, S. ; Permutter, J. ; Rhodes, A. ; Sasano, H. ; Schwartz, J. N. ; Sweep, F. C. ; Taube, S. ; Torlakovic, E. E. ; Valenstein, P. ; Viale, G. ; Visscher, D. ; Wheeler, T. ; Williams, R. B. ... view all 32 authors (2010)
  • Publisher: College of American Pathologists
  • Subject:
    mesheuropmc: skin and connective tissue diseases

Purpose: To develop a guideline to improve the\ud accuracy of immunohistochemical (IHC) estrogen receptor\ud (ER) and progesterone receptor (PgR) testing in breast\ud cancer and the utility of these receptors as predictive\ud markers.\ud Methods: The American Society of Clinical Oncology\ud and the College of American Pathologists convened an\ud international Expert Panel that conducted a systematic\ud review and evaluation of the literature in partnership with\ud Cancer Care Ontario and developed recommendations for\ud optimal IHC ER/PgR testing performance.\ud Results: Up to 20% of current IHC determinations of\ud ER and PgR testing worldwide may be inaccurate (false\ud negative or false positive). Most of the issues with testing\ud have occurred because of variation in preanalytic\ud variables, thresholds for positivity, and interpretation\ud criteria.\ud Recommendations: The Panel recommends that ER and\ud PgR status be determined on all invasive breast cancers and\ud breast cancer recurrences. A testing algorithm that relies\ud on accurate, reproducible assay performance is proposed.\ud Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered\ud positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.(Arch Pathol Lab Med. 2010;134:907–922)
  • References (34)
    34 references, page 1 of 4

    1. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007

    2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007

    3. Fitzgibbons PL, Murphy DA, Hammond MEH, et al: Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (in press)

    4. McCarty KS Jr, Miller LS, Cox EB, et al: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716-721, 1985

    5. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996

    6. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474- 1481, 1999

    7. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000

    8. Thomson CS, Twelves CJ, Mallon EA, et al: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11:419-429, 2002

    9. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581, 2006

    10. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004

  • Metrics
    0
    views in OpenAIRE
    0
    views in local repository
    34
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    UWE Research Repository - IRUS-UK 0 34
Share - Bookmark